1Yakoub-Agha l,Attal M,Dumontet C,et al.Thalidomide in patients with advanced multiple myeloma:a study of 83 patients-repor of the Intergroupe Francophone du Myelome(IFM).Hemtaol J,2002,3(4):185～192.
4Weber DM,Rankin K,Gavino M,et al.Thalidomide with dexamethasone for resistant multiple myeloma.Blood,2000,96:719.
5Dimopoulos MA,Zervas K,Galani E.Thalidomide and dexamethasone combination for multiple myeloma refractory to dexamethasone-based regimens.Blood,2000,96:497a.
6Ahmad l,Islam T,Chanan-Khan A,et al.Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.Bone Marrow Transplant,2002,29(7):577～580.
7Padro T,Ruiz S,Bieker R,et al.Increased angiogenesis in the bone marrow of patients with zcute myeloid leukaemia.Blood,2000,95:2637～2644.
9Raza A,Meyer P,Dutt D,et al.Thalidomide produces trantsfusion infependence in long-standing refractory anemias of patientd with myelodysplastic syndromes.Blood,2001,98(4):958～965.
10(18)Eriksson T,Bjorkman S,Hoglund P.Clinical pharmacology of thalidomide.Eur J Clin Pharmacol,2001,57(5):365～376.
二级参考文献14
1Singtml S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refiractory multiple myeloma. N Engl J Med, 1999,341 : 1565-1571.
2Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol, 1994,87:503-508.
3Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999,94:3717-3721.
4Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia proenitor formation in myelodysplastic syndromes. Blood, 2001,97:1427-1434.
5Aguayo A, Kantarjian H, Manshouri T, et al. Angiosenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000,96:2240-2245,2367-2644.
6Bertolini F, Mancuso P, Gobbi A, et al. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol,2000,28:993-1000.
7Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol, 2000,111:43-51.
8Singhal S, Mehta J, Desikan R,et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med,1999,341:1565-1571.
9Vacca A, Ribatti D, Roncali L,et al.Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol,1994,87:503-508.
10Rajkumar SV, Leong T, Roche PC,et al.Prognostic value of bone marrow angiogenesis in multiple myeloma.Clin Cancer Res, 2000,6:3111-3116.
